Cited 0 times in
Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김종윤 | - |
dc.contributor.author | 정보영 | - |
dc.date.accessioned | 2024-05-30T06:55:29Z | - |
dc.date.available | 2024-05-30T06:55:29Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 1880-4276 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199446 | - |
dc.description.abstract | BackgroundThe real-world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA-AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA-AF population. MethodsOne-year data from 1887 Korean ETNA-AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA-AF registries. ResultsApproximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non-recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (<65 years), youngest-old (65-74 years) and middle-old/oldest-old (>= 75 years) groups were 21.4%, 40.2%, and 38.4%, respectively. Incidence of major or clinically relevant nonmajor bleeding was similar within dose (0.57%-1.71%) and age subgroups (1.26%-1.63%). Incidence of net clinical outcome, a composite of stroke, systemic embolic event, major bleeding, and all-cause mortality, was also comparable among dose subgroups (1.14%-3.10%) and age subgroups (2.28%-2.78%). The percentage of Korean patients receiving non-recommended 30 mg (19.8%) was over twice that of the European population (8.4%). However, the clinical outcomes were generally similar among different populations included in the ETNA-AF study. ConclusionsThe outcomes in the Korean ETNA-AF population are like those in the global ETNA-AF population, with overall low event rates of stroke, major bleeding and all-cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Japanese Society of Cardiac Pacing and Electrophysiology | - |
dc.relation.isPartOf | JOURNAL OF ARRHYTHMIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eue-Keun Choi | - |
dc.contributor.googleauthor | Jong-Il Choi | - |
dc.contributor.googleauthor | Hyoung-Seob Park | - |
dc.contributor.googleauthor | Gyo-Seung Hwang | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.contributor.googleauthor | Jong-Youn Kim | - |
dc.contributor.googleauthor | Dae-Hyeok Kim | - |
dc.contributor.googleauthor | Dong Gu Shin | - |
dc.contributor.googleauthor | Hyung Wook Park | - |
dc.identifier.doi | 10.1002/joa3.12878 | - |
dc.contributor.localId | A00926 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J03721 | - |
dc.identifier.eissn | 1883-2148 | - |
dc.identifier.pmid | 37560283 | - |
dc.subject.keyword | major bleeding | - |
dc.subject.keyword | non‐vitamin K antagonist oral anticoagulants | - |
dc.subject.keyword | real‐world | - |
dc.subject.keyword | registry | - |
dc.subject.keyword | stroke prevention | - |
dc.contributor.alternativeName | Kim, Jong Youn | - |
dc.contributor.affiliatedAuthor | 김종윤 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 546 | - |
dc.citation.endPage | 555 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ARRHYTHMIA, Vol.39(4) : 546-555, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.